Home Alzheimer’s Disease Study Demonstrates Promise for Olaparib in Metastatic Castration-Resistant Prostate Cancer

Study Demonstrates Promise for Olaparib in Metastatic Castration-Resistant Prostate Cancer

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide (Xtandi) or abiraterone (Zytiga) and who had alterations in genes with a role in homologous recombination repair, olaparib (Lynparza) was found to be associated with longer progression-free survival (PFS) and improved measures of response and patient-reported end points than either enzalutamide or abiraterone, according to results from the phase III PROfound trial published in The New England Journal of Medicine

The randomized, open-label clinical trial also found that a benefit was observed in the overall trial population with an alteration in any of the prespecified genes with a direct or indirect role in homologous recombination repair. 

“In men with metastatic castration-resistant prostate cancer who had BRCA1BRCA2, or ATM mutations and who had disease…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments